Accueil › Cancer du poumon › Idaho › Boise
Essais cliniques pour Cancer du poumon à Boise, ID
11 études pour Cancer du poumon recherchent des participants dans et autour de Boise (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Recrutement en coursPhase 3
- Saint Alphonsus Cancer Care Center-Boise, Boise
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Recrutement en coursÉtude observationnelleVolontaires sains bienvenus
- Saint Alphonsus Cancer Care Center-Boise, Boise
- Saint Luke's Cancer Institute - Boise, Boise
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Recrutement en coursPhase 3
- Saint Alphonsus Cancer Care Center-Boise, Boise
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Recrutement en coursPhase 3
- Saint Alphonsus Cancer Care Center-Boise, Boise
- Saint Luke's Cancer Institute - Boise, Boise
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Recrutement en coursPhase 3
- Saint Luke's Cancer Institute - Boise, Boise
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Recrutement en coursPhase 2/3
- St. Luke's Cancer Institute: Boise, Boise
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Recrutement en coursPhase 3
- St. Luke's Cancer Institute, Boise
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Recrutement en coursPhase 2
- Saint Alphonsus Cancer Care Center-Boise, Boise
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Recrutement en coursPhase 2
- Saint Alphonsus Cancer Care Center-Boise, Boise
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Recrutement en coursPhase 2/3
- Saint Alphonsus Cancer Care Center-Boise, Boise
- Saint Luke's Cancer Institute - Boise, Boise
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Recrutement en coursÉtude observationnelle
- Massive Bio SYNERGY-AI site, Boise
Essais pour Cancer du poumon dans d'autres villes
- Houston, TX78 études
- Boston, MA62 études
- New York City, NY60 études
- Los Angeles, CA45 études
- Washington, DC41 études
- Arlington, VA41 études
- Chicago, IL41 études
- Nashville, TN40 études
- Baltimore, MD40 études
- St. Louis, MO39 études
- Columbus, OH37 études
- Philadelphia, PA36 études
Autres études à Boise
- Cancer du poumon non à petites cellules14 études
- Cancer de la prostate8 études
- Leucémie aiguë myéloïde8 études
- Cancer du côlon7 études
- Cancer du sein6 études
- Mélanome6 études
- Cancer colorectal6 études
- Syndrome de détresse respiratoire6 études
- Lymphome de Burkitt5 études
- Traumatisme crânien4 études
- Syndrome post-commotionnel4 études
- Carcinome épidermoïde de la tête et du cou4 études
Source : ClinicalTrials.gov, données récupérées le 5 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.